論文 - 河上　裕

IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides.

Kanekiyo S, Hazama S, Takenouchi H, Nakajima M, Shindo Y, Matsui H, Tokumitsu Y, Tomochika S, Tsunedomi R, Tokuhisa Y, Iida M, Sakamoto K, Suzuki N, Takeda S, Yamamoto S, Yoshino S, Okuno K, Udaka K, Kawakami Y, Matsueda S, Ito K, Nagano H.

Oncol Rep. 39 （ 5 ） 2385 - 2392 2018年05月

研究論文（学術雑誌）, 共著

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Franck Pagès, Bernhard Mlecnik, Florence Marliot, Gabriela Bindea, Fang-Shu Ou, Carlo Bifulco, Alessandro Lugli, Inti Zlobec, Tilman T. Rau, Martin D. Berger, Iris D. Nagtegaal, Elisa Vink-Börger, Arndt Hartmann, Carol Geppert, Julie Kolwelter, Susanne Merkel, Robert Grützmann, Marc Van den Eynd, Anne Jouret-Mourin, Alex Kartheuser, Daniel Léonard, Christophe Remue, Michael H. A. Roehrl, Prashant Bavi, Pamela S. Ohashi, Julia Y. Wang, Linh T.Nguyen, SeongJun Han, Heather L. MacGregor, Sara Hafezi-Bakhtiari, Bradly G. Wouters, Giuseppe V. Masucci, Emilia K. Andersson, Eva Zavadova, Michal Vocka, Jan Spacek, Lubos Petruzelka, Bohuslav Konopasek, Pavel Dundr, Helena Skalova, Kristyna Nemejcova, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Gennaro Cilberto, Michele Maio, Luigi Laghi, Fabio Grizzi, Tessa Fredriksen, Bénédicte Buttard, Mihaela Angelova, Angela Vasaturo, Pauline Maby, Sarah E. Church, Helen K. Angell, Lucie Lafontaine, Daniela Bruni, Carine El Sissy, Nacilla Haicheur, Amos Kirilovsky, Anne Berger, Christine Lagorce, Jeffrey P. Meyers, Christopher Paustian, Carmen Ballesteros-Merino, Jeroen Dijkstra, Carlijn van de Water, Shannon van Lent- van Vliet, Nikki Knijn, Ana-Maria Mușină, Dragos-Viorel Scripcariu, Boryana Popivanova, Mingli Xu, Tomonobu Fujita, Shoichi Hazama, Nobuaki Suzuki, Hiroaki Nagano, Kiyotaka Okuno, Toshihiko Torigoe, Noriyuki Sato, Tomohisa Furuhata, Ichiro Takemasa, Kyogo Itoh, Prabhu S. Patel, Hemangini H. Vora, Birva Shah, ayendrakumar B. Patel, Kruti N. Rajvik, Shashank J. Pandya, Shilin N. Shukla, Yili Wang, Guanjun Zhang, Yutaka Kawakami, Francesco M. Marincola, Paolo A. Ascierto, Daniel J. Sargent, Bernard A. Fox, Jérôme Galon.

Lancet. 391 （ 10135 ） 2128 - 2139 2018年05月

研究論文（学術雑誌）, 共著

Evaluation of the appropriate surgical margin for pigmented basal cell carcinoma according to the risk factors for recurrence: a single-institute retrospective study in Japan.

Nakamura Y, Tanese K, Hirai I, Kameyama K, Kawakami Y, Amagai M, Funakoshi T.

J Eur Acad Dermatol Venereol. [Epub ahead of print] 2018年05月

研究論文（学術雑誌）, 共著

A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma.

Shibao S, Ueda R, Saito K, Kikuchi R, Nagashima H, Kojima A, Kagami H, Sasaki H, Noji S, Kawakami Y, Yoshida K, Toda M.

Oncotarget. 9 （ 30 ） 21569 - 21579 2018年04月

研究論文（学術雑誌）, 共著

Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.

Kamamoto D, Ohara K, Kitamura Y, Yoshida K, Kawakami Y, Sasaki H.

Journal of neuro-oncology 139 （ 2 ） 251 - 259 2018年04月

研究論文（学術雑誌）, 共著

Generation of human immunosuppressive myeloid cell populations in human interleukin-6 transgenic NOG mice.

Hanazawa A, Ito R, Katano I, Kawai K, Goto M, Suemizu H, Kawakami Y, Ito M, Takahashi T.

Frontiers in Immunology. 9 （ 152 ）  2018年02月

研究論文（学術雑誌）, 共著

Ocular Surface and Tear Film Characteristics in a Sclerodermatous Chronic Graft-Versus-Host Disease Mouse Model.

He J, Yamane M, Shibata S, Fukui M, Shimizu E, Yano T, Mukai S, Kawakami Y, Li S, Tsubota K, Ogawa Y.

Cornea. 37 （ 4 ） 486 - 494 2018年01月

研究論文（学術雑誌）, 共著

Functional Role of Lacrimal Gland Fibroblasts in a Mouse Model of Chronic Graft-Versus-Host Disease.

Yamane M, Ogawa Y, Mukai S, Yaguchi S, Kamijuku H, Inaba T, Asai K, Morikawa S, Kawakami Y, Shimmura S, Tsubota K.

Cornea 37 （ 1 ） 102 - 108 2018年01月

研究論文（学術雑誌）, 共著

Inovolbement of local renin-angiotensin system in immunosuppression of tumor microenvironment.

Nakamura K, Yaguchi T, Ohmura G, Kobayashi A, Kawamura N, Iwata T, Kiniwa Y, Okuyama R, Kawakami Y.

Cancer Science. 109 （ 1 ） 54 - 64 2018年01月

研究論文（学術雑誌）, 共著

Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse.

Katano I, Nishime C, Ito R, Kamisako T, Mizusawa T, Ka Y, Ogura T, Suemizu H, Kawakami Y, Ito M, Takahashi T.

Scientific Reports. 7 （ 1 ） 17230 2017年12月

研究論文（学術雑誌）, 共著

Determination of poor prognostic immune features of tumor microenvironment in nonsmoking patients with lung adenocarcinoma.

Kinoshita T, Kudo-Saito C, Muramatsu R, Fujita T, Saito M, Nagumo H, Sakurai T, Noji S, Takahata E, Yaguchi T, Tsukamoto N, Hayashi Y, Kaseda K, Kamiyama I, Ohtsuka T, Tomizawa K, Shimoji M, Mitsudomi T, Asamura H, Kawakami Y.

European Journal of Cancer. 86   15 - 27 2017年11月

研究論文（学術雑誌）, 共著

Role of the autonomic nervous system in the tumor micro-environment and its therapeutic potential.

Xu Z, Shioda S, Jinushi M, Kawakami Y, Ohtaki H, Wang S, Zhao X, Liu Y, Zhou D, Guo Y.

Current pharmaceutical design 23 （ 11 ） 1687 - 1692 2017年11月

研究論文（学術雑誌）, 共著

Human PBMC transferred murine MHC class I/II deficient NOG mice enable long-term evaluation of human immune responses.

Yaguchi T, Kobayashi A, Inozume T, Morii K, Nagumo H, Nishio H, Iwata T, Ka Y, Katano I, Ito R, Ito M, Kawakami Y.

Cellular & Molecular Immunology 14   1-10 2017年11月

研究論文（学術雑誌）, 共著

Reduced Expression of VAMP8 in Lacrimal Gland Affected by Chronic Graft-versus-Host Disease.

Fukui M, Ogawa Y, Mukai S, Kamoi M, Asato T, Kawakami Y, Tsubota K.

Journal of Ophthalmology 2017   1639012 2017年09月

研究論文（学術雑誌）, 共著

CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients.

Matsushita M, Ozawa K, Suzuki T, Nakamura M, Nakano N, Kanchi S, Ichikawa D, Matsuki E, Sakurai M, Karigane D, Kasahara H, Tsukamoto N, Shimizu T, Mori T, Nakajima H, Okamoto S, Kawakami Y, Hattori Y.

Blood Cancer Journal 7   e601 2017年09月

研究論文（学術雑誌）, 共著

Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.

Fukuda K, Funakoshi T, Sakurai T, Nakamura Y, Mori M, Tanese K, Tanikawa A, Taguchi J, Fujita T, Okamoto M, Amagai M, Kawakami Y.

Melanoma Research. 27 （ 4 ） 326 - 334 2017年08月

研究論文（学術雑誌）, 共著

miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer

Shindo Yoshitaro, Hazama Shoichi, Nakamura Yusuke, Inoue Yuka, Kanekiyo Shinsuke, Suzuki Nobuaki, Takenouchi Hiroko, Tsunedomi Ryouichi, Nakajima Masao, Ueno Tomio, Takeda Shigeru, Yoshino Shigefumi, Okuno Kiyotaka, Fujita Yusuke, Hamamoto Yoshihiko, Kawakami Yutaka, Oka Masaaki, Nagano Hiroaki

Oncology Letters 14 （ 2 ） 1355 - 1362 2017年08月

研究論文（学術雑誌）,  ISSN  1792-1074

　概要を見る

<p>MicroRNAs (miRNAs/miRs) regulate the levels of transcripts and serve a critical function in the regulation of tumor microenvironments. Therefore, miRNA levels in cancer tissues are thought to be potential biomarkers for immunotherapy. From a phase I trial of a vaccine treatment using 5 human leukocyte antigen (HLA)-A* 2402-restricted peptides (registration no. UMIN000004948), colorectal cancer (CRC) tissues were obtained from 8 patients and normal colorectal tissues from 5 patients via surgery. From a phase II trial using the same peptides (registration no. UMIN000001791), CRC tissues were obtained from 16 patients from the HLA-A* 2402-matched group and 10 patients from the HLA-A* 2402-unmatched group. These tissues were used for miRNA microarray analysis. As the first step, cancer tissues from the phase I study were used and 10 candidate miRNAs were selected by comparing the miRNA expression between two groups one with improved prognosis and the other with poor prognosis. The miRNAs were subsequently validated using the cases enrolled in the phase II study. Significantly improved prognoses were identified in 16 patients in the HLA-A* 2402-matched group with high expression of miR-196b-5p and low expression of miR-378a-3p and miR-486-5p. There was no difference in prognosis in the 10 patients in the HLA-A* 2402-unmatched group. Therefore, high miR-196b expression and low miR-378a-3p and miR-486-5p expression were indicated as useful biomarkers for prediction of the efficacy of vaccine treatment for patients with metastatic CRC. In a planned phase III study, expression levels of these 3 miRNAs (miR-196b-5p, miR-378a-3p and miR-486-5p) may be useful biomarkers for assessing patients who are likely to have an improved outcome following vaccination.</p>

• Access to Document (DOI)

Autophagy-dependent regulation of tumor metastasis by myeloid cells.

Jinushi M, Morita T, Xu Z, Kinoshita I, Dosaka-Akita H, Yagita H, Kawakami Y.

PLOS ONE. 12 （ 7 ） e0179357 2017年07月

研究論文（学術雑誌）, 共著

MIF: functions in brain and glioblastoma.

Ohta Shigeki, Kawakami Yutaka, Okano Hideyuki

Oncotarget 8 （ 29 ） 46706 - 46707 2017年06月

研究論文（学術雑誌）, 共著,  ISSN  1949-2553

• Access to Document (DOI)

Lack of XAGE-1b and NY-ESO-1 in metastatic lymph nodes may predict the potential survival of stage III melanoma patients

Mori Mariko, Funakoshi Takeru, Kameyama Kaori, Kawakami Yutaka, Sato Eiichi, Nakayama Eiichi, Amagai Masayuki, Tanese Keiji

Journal of Dermatology 44 （ 6 ） 671 - 680 2017年06月

研究論文（学術雑誌）, 共著,  ISSN  0385-2407

　概要を見る

<p>The cancer-testis antigens (CTA) are a large family of tumor-associated antigens expressed by a variety of cancer cells and primitive germ cells of the adult testis and placenta. These tumor-restricted expressing patterns suggest that CTA would be ideal targets for tumor-specific immunotherapy. XAGE-1 is a CTA that was originally identified by computer-based screening, and four transcription variants, XAGE-1a, -1b, -1c and -1d, have been characterized to date. Although the presence of XAGE-1 transcripts has been reported in various cancers, the expression of XAGE-1b in melanoma has not been fully characterized. In this study, we performed immunohistochemical staining of XAGE-1b together with NY-ESO-1, a well-known CTA, in 113 melanoma samples obtained from 84 patients and evaluated their expression in tumor cells. The effects of expression on tumor progression and patient prognosis were analyzed. Both XAGE-1b and NY-ESO-1 were expressed at high levels in lymph node metastasis and skin metastasis samples compared with the primary site (P &lt; 0.01 in XAGE-1b and P &lt; 0.05 in NY-ESO-1). In a subgroup analysis of 22 patients with stage III lymph node metastasis, overall survival was significantly higher in the XAGE-1b and NY-ESO-1 double-negative group than in the other groups (P &lt; 0.05). These results suggest that lack of XAGE-1b and NY-ESO-1 expression could have a positive influence on clinical outcome in patients with melanoma.</p>

• Access to Document (DOI)